Stocktoria
ABEONA THERAPEUTICS INC. ABEO
ABEONA THERAPEUTICS INC. (ABEO) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $5.8M at a 1223.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.799 |
| Retained earnings / assets | -3.38 |
| EBIT / assets | -0.407 |
| Equity / liabilities | 2.638 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ABEO | ABEONA THERAPEUTICS INC. | 4/9 | -5.75 | 4.5 | — |
| KRRO | Korro Bio, Inc. | 2/9 | -13.3 | — | — |
| KYNB | KYNTRA BIO, INC. | 3/9 | — | 0.2 | -78.3% |
| ENSC | Ensysce Biosciences, Inc. | — | — | — | — |
| PCYN | PROCYON CORP | 3/9 | 3.03 | — | — |
| IMNM | Immunome Inc. | 3/9 | 13.87 | — | — |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
About ABEONA THERAPEUTICS INC.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
FAQ
Is ABEO financially healthy?
ABEONA THERAPEUTICS INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ABEO pay a dividend?
No, ABEONA THERAPEUTICS INC. does not currently pay a dividend.
How profitable is ABEO?
In FY2025, ABEONA THERAPEUTICS INC. had a net margin of 1223.1% and a return on equity of 44.7%.
What is ABEO's P/E ratio?
ABEONA THERAPEUTICS INC.'s trailing price-to-earnings (P/E) ratio is about 4.5×, based on its latest annual earnings.
What is the analyst price target for ABEO?
The average Wall-Street price target for ABEONA THERAPEUTICS INC. is $19.71, about 164.3% above the recent price, from 7 analysts.
Is ABEO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ABEONA THERAPEUTICS INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 4.5×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.